Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vandetanib + FOLFOX
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**vandetanib + FOLFOX** is an investigational combination regimen consisting of **vandetanib**, a small molecule tyrosine kinase inhibitor, and **FOLFOX**, a standard chemotherapeutic regimen used primarily in colorectal and other gastrointestinal cancers. - Vandetanib inhibits multiple signaling pathways, including vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases, exerting both antineoplastic and antiangiogenic activity. - FOLFOX is a combination of three drugs: folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. - Fluorouracil is an antimetabolite that interferes with DNA synthesis in rapidly dividing cells. - Oxaliplatin is a platinum-based agent that forms DNA adducts causing cell death. - Folinic acid enhances the effectiveness of fluorouracil. This combination aims to synergize the molecular targeting of vandetanib with the cytotoxic effects of FOLFOX to treat advanced cancers, most commonly in the setting of metastatic colorectal or gastrointestinal malignancies.
- Other names
- ZD6474 + folinic acid + fluorouracil + oxaliplatinvandetanib + folinic acid + fluorouracil + oxaliplatin
02
Targets
EGFR (Epidermal growth factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)DNA
Beyond the preview
Go deeper on vandetanib + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vandetanib + FOLFOX.